Valuation: Novavax, Inc.

Market Cap 1.75B 30.99B 1.54B 1.45B 1.32B 2.48B 168B 2.5B 17.38B 6.72B 85.77B 6.58B 6.44B 276B P/E 2026 *
-17x
P/E 2027 * -47.4x
Enterprise Value 1.97B 34.86B 1.73B 1.63B 1.49B 2.79B 189B 2.81B 19.56B 7.56B 96.48B 7.4B 7.24B 310B EV / Sales 2026 *
5.29x
EV / Sales 2027 * 7.73x
Free-Float
93.03%
Yield 2026 *
-
Yield 2027 * -
1 day+1.23%
1 week+9.89%
Current month+18.50%
1 month+18.12%
3 months+29.45%
6 months+13.86%
Current year+58.15%
1 week 179.9
Extreme 179.9
190
1 month 156
Extreme 156
190
Current year 125
Extreme 125
204.88
1 year 115
Extreme 115
204.88
3 years 65.1
Extreme 65.1
390
5 years 65.1
Extreme 65.1
4,999.99
10 years 65.1
Extreme 65.1
6,550.1
Manager TitleAgeSince
Chief Executive Officer 59 2023-01-22
Director of Finance/CFO 60 2021-08-15
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 73 2010-08-05
Director/Board Member 66 2018-10-31
Director/Board Member 60 2020-06-15
Change 5-day change 1-year change 3-year change Capi.($)
+1.23%+9.89% - - 1.75B
-0.14%+4.33%+9.00%+31.64% 47.97B
-1.69%+1.48%+50.57%+34.53% 44.5B
+2.56%+7.34%+366.69%+608.26% 43.93B
+0.24%+2.85%+10.67%+94.47% 41.03B
-0.62%-1.11%+4.70%+46.02% 29.85B
-0.28%+1.07%+24.58%+155.58% 17.27B
-0.46%+1.20%+26.90%+42.21% 15.3B
-2.21%-4.70% - - 14.82B
+3.37%+9.21%+8.32% - 15.34B
Average +0.20%+2.35%+62.68%+144.67% 30B
Weighted average by Cap. +0.11%+2.86%+79.68%+159.92%

Financials

2026 *2027 *
Net sales 373M 6.59B 327M 309M 281M 527M 35.74B 531M 3.7B 1.43B 18.24B 1.4B 1.37B 58.62B 266M 4.7B 234M 220M 201M 376M 25.5B 379M 2.64B 1.02B 13.02B 999M 978M 41.84B
Net income -108M -1.9B -94.42M -89.08M -81.17M -152M -10.31B -153M -1.07B -412M -5.26B -404M -395M -16.9B -37.93M -670M -33.3M -31.42M -28.63M -53.63M -3.63B -54M -376M -145M -1.86B -142M -139M -5.96B
Net Debt 219M 3.87B 192M 181M 165M 310M 20.98B 312M 2.17B 840M 10.71B 822M 804M 34.42B 303M 5.36B 266M 251M 229M 429M 29.05B 432M 3.01B 1.16B 14.83B 1.14B 1.11B 47.66B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
26-09-25 MX$189.00 +1.23% 22
26-09-24 MX$186.70 +0.38% 462
26-09-23 MX$186.00 0.00% 84
26-09-22 MX$186.00 +1.57% 22
26-09-21 MX$183.13 +6.48% 581
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
10.63USD
Average target price
14.00USD
Spread / Average Target
+31.72%

Quarterly revenue - Rate of surprise